Fennec Pharma reports FY2024 PEDMARK sales $29.6M (+40% YoY); Q4 EBITDA loss $0.6M, cash $26.6M

FENNEC PHARMACEUTICALS INC.

FY2024 net product sales $29.6M, up 40% from $21.3M in 2023; net loss narrowed to $0.07M from $16.0M.
Q4 2024 product sales $7.9M (+13% QoQ); EBITDA loss $0.6M; cash $26.6M at Dec 31, 2024.
Early repaid $13M of ~$32M convertible debt, saving ~$1.5M annual interest; reduces potential dilution.
Full-year operating income $2.6M vs loss $12.8M in 2023; G&A declined QoQ after one-time CEO severance.
PEDMARQSI launched in UK and Germany; Japan trial results (STS-J01) expected H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.